A
Arvinas D
D
ARVN
11.210
USD
-0.18
(-1.58%)
قبل الجلسة
حجم التداول
1,393
الربح لكل سهم
-3
العائد الربحي
-
P/E
-10
حجم السوق
717,002,776
المقالات
العنوان: Arvinas
القطاع: Healthcare
الصناعة: Biotechnology
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases.







